{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:27:08Z","timestamp":1790879228255,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4048,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Studies of acute liver failure from drugs have included cases mostly attributed to acetaminophen (APAP) but have reported limited data on other drugs. We used the United Network for Organ Sharing (UNOS) liver transplant database from 1990 to 2002 to identify recipients and estimate a U.S. population-based rate of liver transplantation due to acute liver failure from drugs. Patients were identified if their diagnosis was acute hepatic necrosis from an implicated drug at the time of transplant. Liver transplantation for drug hepatotoxicity accounted for 15% of liver transplants for acute liver failure over the study period. In our cohort (n = 270), 206 (76%) recipients were female. APAP alone, or in combination with another drug, accounted for 133 (49%) cases. In the non-acetaminophen (non-APAP) group (n = 137), the most frequently implicated drugs were: isoniazid, n = 24 (17.5%); propylthiouracil, n = 13 (9.5%); and phenytoin and valproate in 10 (7.3%) cases each. One-year patient and graft survival for the entire cohort was 77 and 71%, respectively. Among Caucasians (n = 206) and African-Americans (n = 48), APAP only was implicated in 110 (53%) patients and 12 (25%) patients, respectively, and non-APAP drugs were implicated in 96 (47%) patients and 36 (75%) patients, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0004). Among African-Americans in the non-APAP group, 28 (78%) were women. In conclusion four drugs were implicated in 42% of patients undergoing liver transplantation for acute liver failure due to drugs other than APAP. The increased frequency of African-American women undergoing liver transplantation for non-APAP drug induced liver injury warrants further study. (Liver Transpl 2004;10:1018-1023.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.20204","type":"journal-article","created":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T17:07:25Z","timestamp":1090602445000},"page":"1018-1023","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":392,"title":["Liver transplantation for acute liver failure from drug induced liver injury in the United States"],"prefix":"10.1097","volume":"10","author":[{"given":"Mark W.","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Galanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20250326","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/lt.500050102","article-title":"Etiology and outcome for 295 patients with acute liver failure in the United States.","volume":"5","author":"Schiodt","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"R2-9-20250326","doi-asserted-by":"crossref","first-page":"947954","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"R3-9-20250326","first-page":"483490","article-title":"Drug-induced liver disorders: implications for drug development and regulation.","volume":"24","author":"Kaplowitiz","year":"2001","journal-title":"Drug Saf"},{"key":"R4-9-20250326","doi-asserted-by":"crossref","first-page":"133138","DOI":"10.1111\/j.1365-2796.1992.tb00562.x","article-title":"Drug-induced hepatic injury: an analysis of 1100 cases reported to The Danish Committee on Adverse Drug Reactions between 1978 and 1987.","volume":"232","author":"Friis","year":"1992","journal-title":"J Intern Med"},{"key":"R5-9-20250326","doi-asserted-by":"crossref","first-page":"451455","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a french population-based study.","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatol"},{"key":"R6-9-20250326","doi-asserted-by":"crossref","first-page":"219223","DOI":"10.1001\/archinte.1974.00320200029002","article-title":"Hospital admissions due to adverse drug reactions.","volume":"134","author":"Miller","year":"1974","journal-title":"Arch Intern Med"},{"key":"RU7-9-20250326","doi-asserted-by":"crossref","first-page":"474485","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-9-20250326","doi-asserted-by":"crossref","first-page":"289292","DOI":"10.1016\/S0025-6196(12)60534-5","article-title":"Fulminant hepatitis. Mayo Clinic experience with 34 cases.","volume":"60","author":"Rakela","year":"1985","journal-title":"May Clin Proc"},{"key":"R9-9-20250326","first-page":"163169","article-title":"Acute liver failure: clinical features, outcomes analysis, and applicability of prognostic criteria.","volume":"6","author":"Shakil","year":"2000","journal-title":"Liver Transpl"},{"key":"R10-9-20250326","doi-asserted-by":"crossref","first-page":"775792","DOI":"10.1016\/S0025-7125(16)30638-1","article-title":"Drug-induced liver disease.","volume":"73","author":"Lewis","year":"1989","journal-title":"Med Clin North Am"},{"key":"R11-9-20250326","doi-asserted-by":"crossref","first-page":"10141018","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy. A 7-year survey from a public health tuberculosis clinic.","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"R12-9-20250326","first-page":"271279","article-title":"Risk factors for isoniazid-induced liver dysfunction.","volume":"3","author":"Dickenson","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"R13-9-20250326","doi-asserted-by":"crossref","first-page":"465471","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin: a meta-analysis.","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"issue":"suppl","key":"R14-9-20250326","first-page":"7788","article-title":"Drug-induced liver diseases.","volume":"32","author":"Larrey","year":"2000","journal-title":"J Hepatol"},{"key":"R15-9-20250326","doi-asserted-by":"crossref","first-page":"169183","DOI":"10.1055\/s-2002-30102","article-title":"Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.","volume":"22","author":"Chitturi","year":"2002","journal-title":"Sem Liver Dis"},{"key":"R16-9-20250326","first-page":"17271733","article-title":"Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned?","volume":"82","author":"Williams","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-9-20250326","doi-asserted-by":"crossref","first-page":"465469","DOI":"10.1212\/WNL.46.2.465","article-title":"Valproic acid hepatic fatalities. III. U.S. experience since 1986.","volume":"46","author":"Bryant","year":"1996","journal-title":"Neurology"},{"key":"R18-9-20250326","doi-asserted-by":"crossref","first-page":"372377","DOI":"10.1097\/00007890-199408000-00022","article-title":"Acute hepatic failure in seven patients after prophylaxis and therapy with antituberculous agents. Successful treatment with orthotopic liver transplantation.","volume":"58","author":"Meyers","year":"1994","journal-title":"Transplantation"},{"key":"R19-9-20250326","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/106002809202600104","article-title":"Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation.","volume":"26","author":"Bell","year":"1992","journal-title":"Ann Pharmacother"},{"key":"R20-9-20250326","doi-asserted-by":"crossref","first-page":"502506","DOI":"10.1111\/j.1528-1157.1999.tb00748.x","article-title":"The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations.","volume":"40","author":"Annegers","year":"1999","journal-title":"Epilepsia"},{"key":"R21-9-20250326","doi-asserted-by":"crossref","first-page":"346350","DOI":"10.1001\/archpedi.154.4.346","article-title":"Pediatric acetaminophen overdose: risk factors associated with hepatocellular injury.","volume":"154","author":"Alander","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R22-9-20250326","doi-asserted-by":"crossref","first-page":"13741380","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin.","volume":"89","author":"Tolman","year":"2002","journal-title":"Am J Cardiol"},{"key":"R23-9-20250326","first-page":"5862","article-title":"How to use statins in patients with chronic liver disease.","volume":"17","author":"Russo","year":"2003","journal-title":"Cleve Clin J Med"},{"key":"R24-9-20250326","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.7326\/0003-4819-135-1-200107030-00036","article-title":"Kava hepatotoxicity.","volume":"135","author":"Russman","year":"2001","journal-title":"Ann Intern Med"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200408000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T10:42:08Z","timestamp":1743244928000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200408000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.20204","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}